Investigation of plasminogen activator inhibitor-1 (PAI-1) levels in patients diagnosed with polycystic ovary syndrome
DOI:
https://doi.org/10.46328/aejog.v3i1.79Keywords:
Coagulation, Plasminogen activator inhibitor 1, Polycystic ovary syndromeAbstract
Objective:The aim of this study was to investigate the plasma levels of plasminogen activator inhibitor -1 (PAI-1) known as a potent inhibitor of fibrinolysis in women with polycystic ovary syndrome (PCOS) and compare with health controls.
Methods: Forty women with PCOS diagnosed using 2003 revised Rotterdam criteria and 40 healthy women who attended to Adnan Menderes University Department of Obstetrics and Gynecology between July-October 2013 were recruited to this prospective study. We noted all participant’s demographic features, calculated body mass index (BMI), waist hip ratio (WHR), and measured blood pressures. We performed modified Ferriman-Gallwey Score (mFGS) and calculated Luteinizing hormone (LH)/Follicle stimulating hormone (FSH) ratio and homeostatic model assessment insulin resistance (HOMA-IR) of participants. PAI-1 levels were measured by using the Human PAI-1 Elisa test. We used the student T test and Mann-Whitney U test as statistical methods. A p-value less than 0.05 was considered statistically significant.
Results: We found PAI-1 levels, fasting insulin levels, HOMA-IR index, BMI significantly higher in the PCOS group compared with the control group. Mean age of the participants was found lower in the PCOS group. Between the groups we found no statistically significant differences in terms of the LH/FSH ratio, fasting glucose, dehydroepiandrosterone and testosterone levels.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 İhsan Bağlı, Mert Küçük
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AEJOG is an open-access journal which means that through the internet; freely accessible, readable, downloaded, copied, distributed, printed, scanned, linked to full texts, indexed, transferred to the software as data and used for any legal purpose, without financial, legal and technical obstacles. The only authority on reproduction and distribution and the sole copyright role in this field; has been given to authors therefore they can have control over the integrity of their work, so that they are properly recognized and cited. This is in accordance with the BOAI definition of open access.
The content in Aegean Journal of Obstetrics and Gynecology (AEJOG) is protected by copyright. All copyrights of the submitted articles are transferred to the Aegean Journal of Obstetrics and Gynecology within the national and international regulations at the beginning of the evaluation process. Upon submission of their article, authors are requested to complete an assignment of copyright release form. Authors should acknowledge that they will not submit their manuscript to another journal, publish in any other language, or allow a third party to use the article without the written consent of the Aegean Journal of Obstetrics and Gynecology. When an article is published on AEJOG, it is read and reused for free as soon as it is published under a Creative Commons Attribution-NonCommercial 4.0 (CC BY NC 4.0) license. In case the article is rejected, all copyrights are given back to the authors.
The content of the article and all legal proceedings against the journal, if any, are the responsibility of the author. In addition, all financial and legal liability for the copyright of the presented tables, figures and other visual materials protected by law belongs to the authors. It is the responsibility of the corresponding author to report authors scientific contributions and responsibilities regarding the article. In case of any conflict of interest, it is the responsibility of the authors to indicate the conflict of interest in the Disclosure part of the article. Author names will be published as they are listed on the submitted Title page.
